OKYO Pharma Announces Chairman and Founder Acquires Shares

OKYO Pharma (NASDAQ: OKYO) announced that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, acquired 27,051 ordinary shares on NASDAQ on Dec 3, 2025.

Rhea-AI Summary

OKYO Pharma (NASDAQ: OKYO) announced that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, acquired 27,051 ordinary shares on NASDAQ on Dec 3, 2025.

The purchase increases the Chairman's total holding to 10,491,746 shares. The company is developing urcosimod for neuropathic corneal pain, a condition with no FDA-approved therapy.

Positive

• Insider purchase of 27,051 shares on Dec 3, 2025
• Total insider holding increased to 10,491,746 shares

Negative

• None.

Argus Dec 3 session

-5.77% close to close Open Argus

Details

News Market Reaction – OKYO

On Dec 3, the day this news came out, OKYO closed 5.77% below the previous close.

Data tracked by StockTitan Argus for the Dec 3 session.

Market Context

On Dec 3, the day this news came out, the stock closed 5.8% below the previous close. A negative rea...

Analysis

On Dec 3, the day this news came out, the stock closed 5.8% below the previous close. A negative reaction despite continued insider buying fits prior mixed responses to similar news. Earlier acquisition-tagged events produced both gains and declines, with an average move near 5.52%. While the Chairman’s holding climbed to more than 10.49M shares, some past insider purchases were followed by short-term weakness, suggesting that ownership increases alone have not consistently supported the share price once the initial headline impact faded.

Key Figures

Shares acquired: 27,051 shares Chairman total holding: 10,491,746 shares

Shares acquired

27,051 shares

Purchased on NASDAQ by Panetta Partners Limited

Chairman total holding

10,491,746 shares

Post-transaction beneficial holding

Historical Context

5 past events · Latest: Dec 03

5 events

1. Dec 03

   Insider share purchase

   24h Move

   -5.8%

   Chairman-linked entity acquired 27,051 shares, lifting holding above 10.49M.

2. Nov 21

   Insider share purchase

   24h Move

   +11.0%

   Panetta Partners bought 82,018 shares, raising Chairman’s stake to 10.46M.

3. Nov 18

   Conference presentation

   24h Move

   -0.7%

   CEO scheduled OIS XV talk highlighting urcosimod and a 120-patient trial.

4. Oct 29

   Conference participation

   24h Move

   +6.7%

   BIO-Europe presentation on urcosimod Phase 2 data and partnering plans.

5. Oct 16

   Insider share purchase

   24h Move

   +1.9%

   Panetta Partners acquired 210,000 shares, increasing holding to 10.38M.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

neuropathic corneal pain, ocular, fda-approved therapy

3 terms

neuropathic corneal pain medical

"developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition..."

Neuropathic corneal pain is chronic, often severe eye pain caused by damage or malfunction in the tiny nerves of the cornea, where the eye surface can feel burning, stinging, or like something is in it despite little visible damage. It matters to investors because it represents a persistent, hard-to-treat medical need that drives demand for new drugs, diagnostics, devices and regulatory approvals, similar to how fixing a frayed electrical wire stops false alarm signals.

ocular medical

"neuropathic corneal pain (NCP), an ocular condition associated with chronic..."

Relating to the eye or to vision, 'ocular' describes drugs, devices, tests, procedures, or health conditions that affect sight. Investors watch ocular developments because treatments and technologies for vision can create sizable markets, require clinical trials and regulatory approvals, and carry product and safety risks; like upgrading a camera lens, small improvements in ocular products can noticeably change performance, demand, and a company's revenue outlook.

fda-approved therapy regulatory

"nerve-related pain but without an FDA-approved therapy, today announces that..."

A FDA-approved therapy is a medical treatment that the U.S. Food and Drug Administration has reviewed and authorized for sale after assessing its safety and effectiveness. For investors, approval is like a major safety inspection passed and a license to sell broadly: it lowers regulatory risk, can unlock insurance payments and wider markets, and often increases a product’s commercial value and credibility.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LONDON and NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces that Panetta Partners Limited, an entity in which Gabriele Cerrone, Executive Chairman has a beneficial interest, has acquired 27,051 of the Company’s ordinary shares on NASDAQ, bringing his total holding to 10,491,746 shares.

About Urcosimod (Formerly called OK-101)
Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating ocular diseases. Urcosimod has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain, respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to potentially enhance the efficacy of urcosimod within the ocular environment. Urcosimod showed clear statistical significance in multiple endpoints in a 240-patient completed Phase 2, multi-center, double-masked, placebo-controlled trial to treat dry eye disease, and just completed a randomized, placebo-controlled, double-masked Phase 2 trial of urcosimod to treat neuropathic corneal pain.

About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain and dry eye disease, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. A Phase 2 trial of urcosimod to treat neuropathic corneal pain patients was just completed by OKYO.

For further information, please visit www.okyopharma.com.

Inquiries:

Business Development & Investor Relations

Paul Spencer

+44 (0)20 7495 2379

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did OKYO (NASDAQ: OKYO) announce on Dec 3, 2025 about insider buying?

Panetta Partners Limited, linked to Executive Chairman Gabriele Cerrone, acquired 27,051 ordinary shares on Dec 3, 2025.

How many OKYO shares does Chairman Gabriele Cerrone now hold after the Dec 3, 2025 purchase?

His total beneficial holding is reported as 10,491,746 shares.

Which entity executed the OKYO share purchase reported Dec 3, 2025?

The purchase was made by Panetta Partners Limited, an entity in which the Executive Chairman has a beneficial interest.

What program or drug is OKYO Pharma developing mentioned in the Dec 3, 2025 notice?

The company is developing urcosimod to treat neuropathic corneal pain (NCP), a condition without an FDA-approved therapy.

Where were the 27,051 OKYO shares purchased as disclosed on Dec 3, 2025?

The shares were acquired on NASDAQ.